5results about How to "Good dissolution effect" patented technology

The present application belongs to the technical field of white carbon black preparation, and particularly relates to an industrialized preparation method for preparing high-purity low-fluorine white carbon black by taking fluorine-containing silicon slag as raw material, and through mechanical activation, composite alkali leaching, fractional impurity removal, low-temperature crystallization and surface modification. The present application can realize harmless disposal of the fluorine-containing silicon slag and high-value regeneration and utilization of fluorine and silicon resources, has good environmental protection value and economic benefits, and has wide industrialized application prospect.

The invention provides a 3, 5-dihydroxy-4 '-pentylbiphenyl-betaine eutectic as well as a preparation method and application thereof, and belongs to the technical field of pesticide preparation. The invention provides a 3, 5-dihydroxy-4 '-pentylbiphenyl-betaine eutectic which is formed by combining 3, 5-dihydroxy-4'-pentylbiphenyl and betaine through an intermolecular hydrogen bond, and a preparation method of the 3, 5-dihydroxy-4 '-pentylbiphenyl-betaine eutectic. According to the 3, 5-dihydroxyl-4 '-pentylbiphenyl-betaine eutectic and the preparation method thereof, the eutectic is formed by BP and BET, the solubility and the dissolution rate of BP are improved, the application amount of pesticide molecules is reduced, and the 3, 5-dihydroxyl-4'-pentylbiphenyl-betaine eutectic is applied to various plant pathogenic fungi. Results of the embodiment show that the co-crystals formed by BP and BET are combined through hydrogen bonds in a molar ratio of 1: 1, the dissolution effect of the co-crystals is superior to that of the medicine, and the dissolution effect is not affected by the pH environment. Compared with drugs with the same concentration and the drug eutecticum, the drug eutecticum shows the antibacterial activity advantage superior to that of original drug molecules.

The application provides a preparation method of lipoic acid enteric-soluble capsules and relates to the technical field of medicines.The raw materials of the capsule include lipoic acid, and the preparation steps are as follows: lipoic acid is mixed with a disintegrating agent and stirred, a wetting agent is added for granulation, the granulation is discharged to obtain wet granules; the obtained wet granules are dried, sieved and coated to obtain coated granules, the coating liquid includes a binder, an opacifier and a plasticizer; the coated granules are filled with a lubricant into capsules to prepare lipoic acid capsules.The bulk density of the prepared lipoic acid coated granules can reach 0.5-0.7g / mL, which can meet the filling requirements of large-size capsules (such as 600mg capsules), and the lipoic acid coated granules have excellent dissolution performance and high stability.

This application discloses a telmisartan-amlodipine bilayer tablet. The telmisartan layer comprises telmisartan, an alkaline reagent, a binder, a filler, and a lubricant; the amlodipine layer comprises amlodipine besylate, a diluent, a disintegrant, a flow aid, a colorant, and a lubricant. The binder for the telmisartan layer is povidone, with a weight-average molecular weight of 3000–6000 kDa. The diluent for the amlodipine layer is microcrystalline cellulose, specifically a blend of two types. The weight ratio of microcrystalline cellulose PH-102 to PH-302 is 1–4:1–4. The povidone is one or both of povidone K-25 and K-29 / 32. The telmisartan-amlodipine bilayer tablet provided in this application exhibits high stability and dissolution performance similar to the reference tablet.

The invention relates to a solid composition, an agent for improving dissolution of ibuprofen, and a method for improving dissolution of ibuprofen. The present invention addresses the problem of providing a solid composition containing ibuprofen having improved dissolution properties. [Solution] A solid composition which contains (A) ibuprofen and (B) at least one substance selected from the group consisting of noscabine, dextromethorphan, and salts thereof, and which does not contain: (i) a solid composition which does not contain dextromethorphan or a salt thereof and in which ibuprofen and noscabine or a salt thereof are present as different granulated materials; and (ii) a solid composition which does not contain noscabine or a salt thereof and comprises ibuprofen, dextromethorphan or a salt thereof, a hydrogel-forming polymer, and an organic acid or acidic amino acid.